AFT Pharmaceuticals announces a revised 2027 revenue target of over $300 million, driven by strong sales growth, international expansion, and strategic R&D licensing, while maintaining focus on unmet clinical needs across global markets.
Stacked weekly counts; colour by editorial lean. Stuff and The Spinoff lean centre-left, NZ Herald centre-right, others centre.
How press outlets have named this topic, week by week.
Most recent 1 articles linking to this topic.
Up to 12 framings spread across outlets. Each framing is the LLM's one-line characterisation of the article's editorial angle — not a quote.
monetising intellectual property abroad
AFT Pharmaceuticals lifts its 2027 revenue target to above $300 millionSpotted something wrong on this page? Report a correction.